Clinical trials: Respiratory Illness
Asthma, Wheezing
Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.
This protocol is comprised of two separate, but linked, clinical trials for treating preschool-aged children with recurrent severe episodes of wheezing.
- Trial name
- APRIL - OCELOT (NCT01272635)
- Testing
- Azithromycin, Prednisolone
- Where
- 16 sites in United States
- Volunteers
- 607 people
- Sponsor
- Milton S. Hershey Medical Center
RESPIRATORY SYNCYTIAL VIRUS (RSV)
A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age
The purpose of this study is to learn about the safety and immune activity of the vaccine (called RSVpreF) in children 2 to <18 years of age.
- Trial name
- PICASSO (NCT05900154)
- Testing
- RSVpreF 120 µg, RSVpreF 60 µg
- Where
- 17 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tobacco Smoke Pollution
PRIDE: Preventing Respiratory Illnesses During Childhood Study
Environmental tobacco smoke (ETS0, also known as secondhand smoke, is the combination of smoke given off by the burning end of a tobacco product and the smoke exhaled by the smoker.
- Trial name
- PRIDE (NCT00927264)
- Testing
- Motivational Interviewing Intervention for ETS Reduction, Educational Program for ETS Reduction
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
COVID-19
A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse. Participants with mild-to-moderate COVID-19 will receive bamlanivimab via an injection into a vein.
- Trial name
- BLAZE-5 (NCT04701658)
- Testing
- Bamlanivimab
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Other Acute Illnesses Presenting to the Hospital, Heart Failure
Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
This VA QUERI Partnered Evaluation Initiative will evaluate the impact of an immersive Point-of-care Ultrasound (POCUS) Training Course on provider skill acquisition and retention; the frequency of POCUS use by trained providers…
- Conditions
- Other Acute Illnesses Presenting to the Hospital, Heart Failure, Pneumonia, Deep Venous Thrombosis
- Trial name
- NCT03296280
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
COVID-19
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19.
- Trial name
- BLAZE-4 (NCT04634409)
- Testing
- Bamlanivimab, Etesevimab, VIR-7831
- Where
- 141 sites in United States, Argentina and 1 more
- Volunteers
- 1,755 people
- Sponsor
- Eli Lilly and Company
Respiratory Viral Infections, Respiratory Syncytial Virus Infections
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age
The overall objective of the MEDI-534 clinical development program is to evaluate the safety, efficacy and tolerability of MEDI-534 for the prevention of serious RSV and PIV3 disease in young infants.
- Conditions
- Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human
- Trial name
- CP149 (NCT00493285)
- Testing
- MEDI-534
- Where
- 30 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Respiratory Syncytial Virus (RSV)
Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
This was a non-interventional, prospective, multi-center study with no control group designed to assess the effectiveness of palivizumab in a population of infants at high-risk of serious Respiratory Syncytial Virus (RSV) illness…
- Trial name
- SUNRISE (NCT02282982)
- Volunteers
- 359 people
- Sponsor
- AbbVie
COVID-19
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a…
- Trial name
- CONCOR-1 (NCT04348656)
- Testing
- Convalescent plasma
- Where
- 73 sites in United States, Brazil and 1 more
- Volunteers
- 940 people
- Sponsor
- Hamilton Health Sciences Corporation
RSV Illness in ≤12 Months of Participants
A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness
The primary objective of this study is to describe the effect of a single dose of medication compared to placebo in the upper respiratory tract in previously healthy children less than or equal to 12 months of age who are…
- Trial name
- NCT00421304
- Testing
- Motavizumab
- Where
- 35 sites in United States, Australia and 3 more
- Volunteers
- 118 people
- Sponsor
- MedImmune LLC
Respiratory Illness
NICU Asthma Education and Secondhand Smoke Reduction Study
Premature infants have a significantly increased risk for developing respiratory illnesses and asthma. Secondhand smoke (SHS) also is clearly associated with increased breathing problems in children, thus exposure to smoke makes…
- Trial name
- NCT00499915
- Testing
- Secondhand Smoke Reduction and Smoking Cessation Counseling, Asthma Education
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Respiratory Disease, Asthma in Children
Utility of Continuous Pulse Oximetry for Pediatric Patients With Stable Respiratory Illness
This is a randomized, prospective study to determine if there is a difference in hospital length of stay between patients receiving continuous hardwire cardiorespiratory monitoring and those receiving intermittent vital signs…
- Conditions
- Respiratory Disease, Asthma in Children, Pneumonia in Children, Bronchiolitis Acute
- Trial name
- NCT04407806
- Testing
- Continous Pulse oximeter, Intermittent Pulse oximeter
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Corewell Health East
Asthma, Wheezing
AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department
AZ-SWED is a parallel group, double blind, placebo control efficacy clinical trial with two separate hypotheses. The trial compared the 5-day outcome of preschool children presenting to an Emergency Department (ED) with an acute…
- Trial name
- AZ-SWED (NCT04669288)
- Testing
- Azithromycin
- Where
- 8 sites in United States
- Volunteers
- 840 people
- Sponsor
- University of Arizona
Upper Respiratory Tract Infection, Lower Respiratory Tract Infection
RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
RSV infections can develop into serious, life threatening conditions among immunocompromised patients. The objective of this study (ADMA 001) is to evaluate the safety and efficacy of RI-001 for the prevention of lower…
- Trial name
- NCT00632463
- Testing
- RI-001
- Where
- 19 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- ADMA Biologics, Inc.
Participants Less Than 12 Months of Age With RSV Illness
A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness
This was a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to determine the effect of a single 30 mg/kg intramuscular (IM) dose of motavizumab on viral load and motavizumab levels in the upper respiratory…
- Trial name
- NCT00435227
- Testing
- Motavizumab
- Where
- 31 sites in United States
- Volunteers
- 12 people
- Sponsor
- MedImmune LLC
Severe Acute Respiratory Illness
Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness
Respiratory viruses are a significant cause of hospitalization for respiratory tract infections. This study will evaluate the safety, effectiveness, and tolerability of nitazoxanide (NTZ) in treating severe acute respiratory…
- Trial name
- NTZ-SARI (NCT02057757)
- Testing
- Nitazoxanide
- Where
- 6 sites in Mexico
- Volunteers
- 260 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Viral Infection, Acute Respiratory Infection
Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway
Rapid diagnosis and precise treatment have become possible with multiplex polymerase chain reaction (PCR) panels that can identify a variety of causative agents of acute respiratory illnesses such as bacterial and viral…
- Conditions
- Viral Infection, Acute Respiratory Infection, Upper Resp Tract Infection
- Trial name
- URGENT (NCT05467007)
- Testing
- BioFire® Respiratory Panel 2.1-EZ
- Where
- 2 sites in United States
- Volunteers
- 360 people
- Sponsor
- Andrew Meltzer
COVID-19
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19.
- Trial name
- BLAZE-1 (NCT04427501)
- Testing
- LY3819253, LY3832479, LY3853113
- Where
- 12 sites in United States
- Volunteers
- 3,307 people
- Sponsor
- Eli Lilly and Company
Influenza, Acute Respiratory Infection
FluSAFE: Flu SMS Alerts to Freeze Exposure
Influenza infection results in an estimated 31 million outpatient visits, 55,000 to 974,200 hospitalizations, and 3,000 to 49,000 deaths.
- Conditions
- Influenza, Acute Respiratory Infection, Influenza-like Illness
- Trial name
- NCT03274310
- Testing
- Educational text messages
- Where
- United States
- Volunteers
- 1,918 people, healthy volunteers welcome
- Sponsor
- Columbia University